A clinical trial of CER-001 for treatment of sever eye disorder
Latest Information Update: 24 Mar 2024
At a glance
- Drugs CER 001 (Primary)
- Indications Eye disorders
- Focus Therapeutic Use
Most Recent Events
- 24 Mar 2024 New trial record
- 14 Mar 2024 According to an ABIONYX Pharma media release, the company has received eur1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology. This grant will help finance studies on the CER-001 drug candidate. Payment will be made in two instalments, once development has begun and company has made the corresponding investment in its 100per cent ophthalmology subsidiary, Apogeye Pharma.